Nestle sells peanut-allergy treatment business to Stallergenes Greer


By Adria Calatayud

Nestle said it has sold its Palforzia peanut-allergy treatment business to biopharmaceutical company Stallergenes Greer.

The Swiss consumer-goods company said Monday that it will receive milestone payments and royalties from Stallergenes Greer. The deal was closed upon signing, Nestle said.

The sale allows Nestle’s health-science operations to focus on its core strengths and key growth drivers, the unit’s Chief Executive Greg Behar said.

Nestle last year said that it would conduct a strategic review of Palforzia after a slower-than-expected adoption by patients and healthcare professionals.

Write to Adria Calatayud at

This article was originally published by Read the original article here.

Previous articleDow Jones Newswires: Chinese property developer stocks jump on easing mortgage policy
Next article: China property stocks rally as better news challenges record media negativity.


Please enter your comment!
Please enter your name here